The CJC-1295 / Ipamorelin combination is a physician-designed peptide protocol that synergistically supports growth hormone release and overall regenerative function. CJC-1295 acts as a growth hormone-releasing hormone (GHRH) analog, promoting sustained pulsatile release of endogenous growth hormone, while Ipamorelin functions as a selective growth hormone secretagogue, enhancing peak release without significantly affecting cortisol or prolactin levels.
Together, this stack is frequently used in clinical practice to support lean body composition, tissue repair, recovery, and age-related wellness. Its mechanism leverages natural endocrine pathways, offering a controlled and physiologic approach to growth hormone optimization. Clinicians incorporate CJC-1295 / Ipamorelin into personalized protocols with careful monitoring to maximize patient outcomes while ensuring safety and adherence to regulatory standards.
